Replies to post #70863 on OWC Pharmaceutical Research Corp (OWCP)

[moxa1]

Easy IMO. Very strong buying interest here.

[bybtrader]

Welcome back! You were missed :)

And yes I agree. It should reach about $3 with the anticipation of efficacy results!

Go OWCP!

[Moonbound]

Welcome back feller! Onwards and upwards my friend!

OWCP

[RobotDroid]

That could be a realistic number, unlike other projections. Holding $3 is the next step if it reaches it. Good luck.

[skyhawk66]

Spot On Feller and welcome back! The Efficacy Results will be the First of Many Solid Factors that will send the PPS past the last high of $3.20's and into Blue Sky territory Again. This will be followed shortly by the Bigger Hammer which will be "The Pill". It just gets better and better with OWCP! Buying All I Can at these Prices.

We have all the patented delivery systems: (GWPH has 1 Patent)) (OWCP has 8)

OWC Pharmaceutical Research Corp Completes Development of Its Medical Cannabis Sublingual Tablet.

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it has completed the development of a proprietary, cannabinoid-enriched sublingual tablet (the "Tablet") for the administration of medical cannabis.

The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient's blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking. 10 Million patients will take a tablet specific dosage who otherwise wont smoke it.

The Company is working towards having the Tablet approved by the Israeli Medicinal Cannabis Unit under the Ministry of Health office for use within the country's sanctioned medical cannabis program, as well as talking with potential licensees of the technology in the United States. Longer term, management expects to establish clinical tests of the Tablet in protocols for Multiple Myeloma, Post-Traumatic Stress Disorder (PTSD), and Fibromyalgia.

Delivery Systems:
1.Creams
2.Tablet
3.Nasal Spray

We will be able to partner with other cannabis to generate tens of millions in revenue for these delivery systems.

[Hoya Saxa]

We missed you man!